Literature DB >> 7049116

Gaucher's disease: a disease with chronic stimulation of the immune system.

Y Shoenfeld, L A Gallant, M Shaklai, E Livni, M Djaldetti, J Pinkhas.   

Abstract

Concentrations of IgA, IgG, and IgM were measured in 25 patients with Gaucher's disease. The mean of each was significantly higher than that generally observed in healthy adults. A direct correlation was noted between IgA and IgG concentrations and age. Patients who underwent splenectomy had IgM concentrations significantly lower than those of persons who did not. In two of 25 patients, multiple myeloma of the nonsecretory type developed. The migration inhibition factor (MIF) test performed with the lymphocytes of our patients was positive to glucocerebroside in four of 17 patients, to glucocerebrosidase in four of 19 patients, and to the extracts of the spleen of a patient with Gaucher's disease in three of eight patients. The results of al MIF tests were negative in six control subjects with splenomegaly of other causes. Our results suggest that in Gaucher's disease there is chronic stimulation of the humoral immune system. The first expression of this stimulation is the production of polyclonal immunoglobulins and, in due time, the development of monoclonal immunoglobulin as well as multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049116

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  27 in total

1.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

2.  Rheumatologic aspects of lysosomal storage diseases.

Authors:  Bernhard Manger; Eugen Mengel; Roland M Schaefer
Journal:  Clin Rheumatol       Date:  2006-05-06       Impact factor: 2.980

3.  The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.

Authors:  Tamar H Taddei; Katherine A Kacena; Mei Yang; Ruhua Yang; Advitya Malhotra; Michael Boxer; Kirk A Aleck; Gadi Rennert; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

Review 4.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

5.  Transient monoclonal gammopathy in hydralazine induced lupus erythematosus.

Authors:  Y Shoenfeld; D Isenberg
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-15

6.  Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

7.  Gaucher's disease and mesangiocapillary glomerulonephritis in childhood--a coincidence?

Authors:  R Halevi; M Davidovitz; S Mann; M Ben-Bassat; H Stark; B Eisenstein
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

Review 8.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

9.  Isolation of proliferation factor of immature T-cell clone in concanavalin A-stimulated splenocyte culture supernatant.

Authors:  Yasuhiro Kohama; Shinji Shinoda; Katsunobu Hagihara; Takeshi Hashimoto; Asuka Yamaguchi; Akihiro Nakamura; Takahiro Tsuchiya; Kazutake Tsujikawa; Hiroshi Yamamoto
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

10.  Natural autoantibodies in sera of patients with Gaucher's disease.

Authors:  Y Shoenfeld; A Beresovski; D Zharhary; Y Tomer; M Swissa; E Sela; A Zimran; S Zevin; B Gilburd; M Blank
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.